Grb7 is not a substrate of the insulin receptor tyrosine kinase activity. Grb7 binds the activated tyrosine kinase loop of the insulin receptors. Two domains of Grb7 are implicated in the insulin receptor binding: the SH2 domain and the PIR (phosphotyrosine interacting region). The role of these two domains in the interaction with the insulin receptor was already reported for Grb10 and Grb14, the other members of the Grb7 family of proteins. However, the relative importance of these domains varies, considering the receptor and the Grb protein. These dierences should be a determinant of the speci®city of the receptor tyrosine kinase-Grbs binding, and thus of the implication of Grb7/10/14 in signal transduction.
Introduction
Growth factors are acting through high-anity receptor tyrosine kinases inserted in the plasma membrane of target cells. After ligand binding the receptors are activated, and phosphorylated on tyrosine residues that act as anchoring sites for SH2-containing intracellular eectors. These signaling proteins are molecular adapters, like Shc, Grb2 or the p85 regulatory subunit of the phosphotidylinositol 3-kinase, or possess enzymatic activities, like the tyrosine phosphatase SHP2, the tyrosine kinase Src or the phospholipase Cg (Fantl et al., 1993; Ullrich and Schlessinger, 1990) . Molecular adapters are formed by the juxtaposition of various protein-protein interacting domains, implicated in protein activation cascades. A new family of adapters has recently emerged, the Grb7 family of proteins, comprising Grb7, Grb10 and Grb14. The members of this family were originally cloned by interaction with EGF receptor, using the CORT (cloning of receptor target) system (Daly et al., 1996; Margolis, 1994; Ooi et al., 1995) , and the use of the yeast two-hybrid technology has emphasized their implication in signal transduction (Daly, 1998) . These adapters bind also other tyrosine kinase receptors, like erbB2, Ret, Elk, PDGF receptors, insulin receptors and IGF-1 receptors (Daly et al., 1996; Dey et al., 1996; Hansen et al., 1996; Kasus-Jacobi et al., 1998; Dong et al., 1997; Laviola et al., 1997; Liu and Roth, 1995; Morrione et al., 1997; O'Neill et al., 1996; Pandey et al., 1995 Stein et al., 1994 Wang et al., 1999; Yokote et al., 1996) . In addition, Grb10 and Grb7 can interact with other families of proteins. Cytokines receptors like the GH receptor, the tyrosine kinases Jak2 and Tec, and the kinases MEK and Raf were found in association with Grb10 (Mano et al., 1998; Moutoussamy et al., 1998; Nantel et al., 1998) . After EGF or PDGF stimulation Grb7 is associated with Shc, another molecular adapter, or with the tyrosine phosphatase SHP2 (Keegan et al., 1994; Stein et al., 1994; Yokote et al., 1996) .
Although their biological role is not yet elucidated, an increasing number of studies strongly argue in favor of an important role of the Grb7/10/14 proteins in tyrosine kinase signaling and in the development of cancers (for review see Daly, 1998) . The ®rst observation was the overexpression of Grb7 together with erbB2 in numerous breast tumors and cell lines (Stein et al., 1994) . A variant of Grb7, lacking the C-terminus SH2 domain, is likely to be involved in the cell invasion and metastatic progression of human oesophageal carcinomas (Tanaka et al., 1998) . Grb10 and Grb14 are also overexpressed in several breast and prostate cancer cell lines (Daly et al., 1996; Dong et al., 1997) . Recent studies propose a physiological role of Grb7 in kidney development and cell migration (Han and Guan, 1999; Leavey et al., 1998) , and of Grb14 in insulin signal transduction (Kasus-Jacobi et al., 1998) .
Proteins of the Grb7 family contain a N-terminal proline rich domain, a PH domain and a C-terminal SH2 domain. The SH2 domain is responsible for the interaction of these Grbs proteins with all their identi®ed partners. However, it has recently been shown that the region located between the PH and the SH2 domains of Grb10 and Grb14 is a new binding domain, which has been called BPS or PIR and is implicated in the receptor tyrosine kinase binding (He et al., 1998; Kasus-Jacobi et al., 1998) . The relative role of the BPS/PIR and of the SH2 domains depends on the Grb isoform and the tyrosine kinase receptor considered. In the case of Grb10, the SH2 domain mediates the EGF receptor interaction, while the BPS/ PIR is responsible for the IGF-1 receptor binding, and both domains can associate with the insulin receptor (He et al., 1998) . Interestingly, the interaction between Grb14 and the insulin receptor is mainly due to the PIR, whereas the SH2 domain is dispensable for it (Kasus-Jacobi et al., 1998) . Numerous recent studies are in favor of a role of Grb10 and Grb14 in insulin signal transduction, as mentioned above, but a potential role for Grb7 in these pathways has not been investigated. The purpose of the present paper was then to study if Grb7 could also associate with the insulin receptors, and to determine the domains of Grb7 responsible for this association.
Results
Grb7 was cloned by a two-hybrid screen of a rat liver cDNA library performed with the intracellular domain of the insulin receptor (Kasus-Jacobi et al., 1998). Grb7 was already known to bind dierent tyrosine kinase receptors, like the EGF receptor (Fiddes et al., 1998; Margolis et al., 1992) and Ret (Pandey et al., 1996) , but this is the ®rst evidence for an interaction with the insulin receptor (IR). To compare the Grb7/ IR interaction with the interaction of Grb7 with various tyrosine kinase receptors we quantitated them in the two-hybrid system. Yeasts were transformed with the dierent couples of plasmids, and the bgalactosidase activity, re¯ecting the interaction, was measured using a liquid assay. We veri®ed the expression levels of the hybrid proteins by Western blots, using anti-GAL4 activation domain antibodies for Grb7 and Shc fusions, or anti-LexA antibodies for the receptors fusions. Shc and Grb7 fusions were expressed to similar levels (data not shown). As illustrated in Figure 1 receptor fusions are nicely expressed in yeast, at the exception of the EGF receptor. We veri®ed the binding ability of these receptors by measuring their interaction with Shc as a control (Table 1) . Shc interacted with all receptors tested, and the interaction was in the same range of order as the positive control measured simultaneously (the Ras/Raf interaction: 40+4 units of Miller). These data suggest that the fusion constructs are functional in the two-hybrid system. The coexpression of Grb7 with the insulin receptor induced a b-galactosidase activity signi®cantly higher than with the other tyrosine kinase receptors: this activity was sixfold higher than with the FGF receptors and Ret, and 100-fold higher than with the EGF receptors ( Table 1) . The low interaction of Grb7 with the EGF receptors is unlikely to be due to the weak expression of this receptor as shown by the control interaction with Shc. Thus, Grb7 is likely to preferentially interact with the insulin receptor, when compared to EGFR, Ret and FGFR.
The interaction between the insulin receptor and Grb7 was con®rmed in vitro using a GST pull-down assay, and in vivo in transiently transfected COS cells. CHO-IR cell lysates from control and insulin-stimulated cells were incubated with GST-Grb7 fusions immobilized on glutathion-sepharose beads. As shown in Figure 2a , only the activated insulin receptor coprecipitated with GST-Grb7, and not with control GST. COS cells were transiently transfected with the insulin receptor and Grb7. Insulin stimulates tyrosine phosphorylation of the insulin receptor b subunit in the cell lysates ( Figure 2b , lane 4). The lysates were immunoprecipitated with anti-Grb7 antibodies prior to immunodetection with anti-phosphotyrosine antibodies. As shown in lane 2, insulin stimulates the association between the activated insulin receptors and Grb7. Control blots with anti-Grb7 antibodies and anti-IR antibodies con®rmed that similar amounts of Grb7 and insulin receptors were expressed (Figure 2b , lower blots). In control serum starved cells very few insulin receptors were tyrosine phosphorylated. However, the immunoprecipitation with the Grb7 antibodies concentrated the low amount of activated insulin receptors (Figure 2b , compare lanes 3 and 1). This further argues in favor of an interaction between the activated insulin receptor and Grb7. It is noticeable that Grb7 overexpressed in COS cells was not detected with the anti-phosphotyrosine antibodies, even after immunoprecipitation (see Figure 2b ). This implies that Grb7 is not a substrate of the insulin receptor tyrosine kinase activity.
The binding between Grb7 and the insulin receptors was further studied in vivo in the SK-BR-3 cell line, expressing high levels of Grb7, and in rat tissues. Insulin receptors and Grb7 are nicely expressed in SK-BR-3 cells (Figure 2c , lanes 1 and 2). Immunoprecipitation of the cell lysate with anti-Grb7 antibodies showed an association of the insulin receptors with Grb7 after insulin stimulation ( Figure 2c , lane 4). The tissue distribution of Grb7 in the rat was studied by Figure 1 Immunoblot analysis of the receptor tyrosine kinase hybrid proteins. Yeast extracts from strains coexpressing the Gal4AD-Grb7 or Gal4AD-Shc proteins and the dierent LexAreceptors hybrid proteins as indicated were immunodetected using anti LexA antibodies. C: control yeast strain transformed with the empty pLexA plasmid Northern blot analysis. Grb7 mRNA were highly expressed in liver, kidney and placenta and to a lower level in lung, but they could not be detected in other tissues (unshown results). This pattern of expression was similar to the mouse (Margolis et al., 1992) , but diers from human (Frantz et al., 1997) . The in vivo IR-Grb7 association was then studied in rat liver. Anaesthetized starved rats were injected intravenously with insulin or saline, and after 10 min liver proteins were extracted and immunodetected with anti-phosphotyrosine antibodies. As shown in Figure 2d , lane 4, a faint band was detected in the anti-Grb7 immunoprecipitate, giving evidence that liver insulin receptors were associated with Grb7 after insulin stimulation. All together these experiments clearly show that Grb7 binds the phosphorylated insulin receptors in vitro, and more importantly in vivo with the endogenous amounts of proteins.
To determine if the IR-Grb7 interaction involves a particular phosphorylated tyrosyl residue, we measured the binding of Grb7 with insulin receptors mutated on dierent tyrosyl residues using the two-hybrid system ( Figure 3a) . As expected, Grb7 cannot bind the kinaseinactive insulin receptor (K1018A). Mutation of the juxtamembrane tyrosyl residue (Y960F), or deletion of the tyrosyl residues located in the C-terminus of the insulin receptor (D1316/1322) did not alter the interaction with Grb7. However, mutation of each tyrosyl residue present in the tyrosine kinase loop of the insulin receptor (Y1146F, Y1150F and Y1151F) signi®cantly reduced the interaction with Grb7. The greatest reduction (60%) was observed for the Y1151F mutant. All receptor mutants were expressed to similar levels in this assay (Figure 3b) . We have previously reported that the interaction between Shc and the insulin receptor was not modi®ed by the mutations aecting the tyrosine kinase loop. This implies that the tyrosine kinase activity of these mutants was not signi®cantly altered (Kasus-Jacobi et al., 1998) . Thus, these results show that Grb7 binds the activated tyrosine kinase loop of the insulin receptors. However, since none of the mutations tested abolished the IR/ Grb7 interaction, it cannot be excluded that additional regions of the insulin receptor are implicated in this interaction.
It has been reported previously for Grb10 and Grb14 that both SH2 and PIR (also called BPS) domains are able to mediate the interaction with the insulin receptor (He et al., 1998; Kasus-Jacobi et al., 1998) . To assess if the same domains of Grb7 bind the Starved rats were injected with saline or insulin. After 10 min., liver extracts were prepared, separated by SDS ± PAGE, and immunodetected with anti-phosphotyrosine and anti-Grb7 antibodies. Lanes 1 and 2, crude liver extracts; lanes 3 and 4, liver extracts immunoprecipitated with anti-Grb7 antibodies
Binding of Grb7 to the insulin receptor A Kasus-Jacobi et al activated insulin receptors, and thus if the corresponding PIR region of Grb7 is also a functional proteinprotein interacting domain, we measured the binding eciency of dierent deletion mutant of Grb7 in the two-hybrid system. All Grb7 deletion mutants were nicely expressed in yeast (Figure 4b) . Deletion of the SH2 domain signi®cantly reduced the IR/Grb7 interaction, whereas deletion of both the PIR and SH2 totally suppressed it (Figure 4a ). This implies that both domains are important for the binding of Grb7. The interaction displayed by the PIR-SH2 region represented about 50% of the full length Grb7 interaction. When expressed separately each of the two domains SH2 and PIR retained a binding activity towards the insulin receptor. It must be noticed that the expression of the SH2 domain is toxic for the yeast: the expression of the PIR ± SH2 and the SH2 constructs signi®cantly slowed down the growth of the yeast. The interactions between the dierent domains of Grb7 and the insulin receptor were further examined using GST pull-down assays. CHO-IR lysates from control and insulin stimulated cells were incubated with various GSTGrb7 fusions. The same amounts of the dierent GST fusions were used. Retained proteins were separated by gel electrophoresis and immunodetected using antiphosphotyrosine antibodies. The blots were then stripped and immunodetected with anti-IR antibodies ( Figure 5 ). The insulin receptor binding ability of Grb7 is reproduced by the PIR ± SH2 domain of the protein (Figure 5, lanes 4 and 8) . The two domains, PIR and SH2, precipitated the activated insulin receptor (lanes 14 and 16). However, in this assay the SH2 domain retained most of the full length protein insulin receptor binding ability, whereas the PIR coprecipitated only few receptors (compare lanes 14 and 16). A mutation of the conserved arginyl residue of the SH2 domain implicated in phosphotyrosine recognition (R461K) drastically decreased the interaction of the insulin receptor with the full length Grb7 and the PIR ± SH2 region (lanes 6 and 10). In addition, the SH2 R461K domain did not bind the insulin receptors (lane 18).
Together these experiments show that the PIR and the SH2 are two binding domains of Grb7, both involved in the interaction with the insulin receptor. We then investigated the eect of mutation of the insulin receptor tyrosyl residues on the interaction with the PIR domain of Grb7. As reported in Table 2 , the IR ± PIR association was abolished by mutation of Y1150 or Y1151, and was more than 90% decreased by mutation of Y1146. Mutation of the tyrosyl residues in the juxtamembrane or the C-terminus regions did not alter the IR ± PIR interaction. These eects are similar to those observed with the PIR of Grb14 and Grb10 (He et al., 1998; Kasus-Jacobi et al., 1998) . This suggests that the PIR of the three proteins display similar binding speci®cities, and speci®cally interact with the phosphorylated kinase loop of the insulin receptors.
Dierent results were obtained concerning the respective role of the PIR and SH2 domains in the interaction with the insulin receptors (He et al., 1998; Kasus-Jacobi et al., 1998) . To decipher the implication of the PIR and SH2 domains of Grb7 and Grb14 in the insulin receptor binding, we used the GST pulldown experiments to compare the amount of insulin receptors retained by the dierent domains. The GST fusions were quanti®ed after production, and veri®ed by Ponceau red staining of the blots (data not shown) to use equal amounts of the various fusions. As shown in Figure 6 , the PIR of both Grb14 and Grb7 retained insulin receptors, but the PIR of Grb14 seemed more ecient (lanes 2 and 4). On the opposite, the GST ± SH2 domain of Grb14 did not bind the insulin receptors, as previously shown (Kasus-Jacobi et al., 1998), whereas the SH2 domain of Grb7 eciently retained it (lanes 6 and 8).
Discussion
This study gives compelling evidence that the Grb7 molecular adapter binds the insulin receptor. Insulin induces the IR-Grb7 interaction in cells expressing physiological levels of the proteins, suggesting that Grb7 is implicated in insulin signaling. Grb7 was already known to bind various tyrosine kinase receptors after ligand activation, like the EGF receptor, erbB2, erbB3, the PDGF receptor and Ret (Fiddes et al., 1998; Margolis et al., 1992; Pandey et al., 1996; Stein et al., 1994; Yokote et al., 1996) , and our study suggests that Grb7 preferentially binds the insulin receptor. Grb7 is not a substrate of the insulin receptor tyrosine kinase activity. In contrast, it has been reported that Grb7 is phosphorylated on tyrosine residues when it binds the EGF receptor and erbB2 (Pandey et al., 1996; Stein et al., 1994; Tanaka et al., 1998) , but not the PDGF receptor (Yokote et al., 1996) . Grb10 and Grb14, members of the same family of adapters, display similar properties: they bind various activated tyrosine kinase receptors, and if they are tyrosine phosphorylated by some of them (Mano et al., 1998) In vitro interaction between Grb7 domains and the insulin receptor. The indicated GST-Grb7 fusions (5 mg) were incubated with CHO-IR lysates as described in Figure 2a . Bound proteins were immunodetected using anti-phosphotyrosine antibodies (upper panel). After stripping the blots were then immunodetected with anti-IRb antibodies (lower panel). The anti-IRb antibodies strongly cross-reacted with proteins present in the GST ± PIR lanes, precluding the use of these lanes (lower panel, lanes 13 and 14). These blots are representative of three similar experiments Table 2 Interaction of the Grb7 PIR with the insulin receptor mutants
Quanti®cation of the indicated interactions were performed in the two-hybrid system as described in Figure 3 . Results are expressed as percentage of the interaction with the wild-type receptor (representing 99 units of Miller) 1998). The other families of proteins known to bind insulin receptors are IRSs and Shc. They are substrates of the receptor tyrosine kinase, and their phosphorylated tyrosyl residues recruit a spectrum of SH2 domain containing proteins (White and Yenush, 1998) . This implies that the signaling pathways initiated after Grb7/10/14 binding to insulin receptors are mediated by mechanisms that are dierent from those described after IRSs and Shc phosphorylation. Two domains of Grb7 are implicated in the insulin receptor binding, the PIR (also called BPS) and the SH2 domain. Thus, all three members of the Grb7 family of proteins, Grb7, Grb10 and Grb14 are able to bind the activated insulin receptors through their PIR and SH2 domains. The PIR of Grb7, which displays respectively 51 and 47% of identity with the corresponding regions of Grb10 and Grb14, is then also a binding domain, able to mediate an interaction with the insulin receptor. Mutation of tyrosyl residues present in the activation loop of the insulin receptor drastically reduce the binding of the Grb7 PIR. Similarly, the PIR of Grb10 and Grb14 does not bind insulin receptors containing the Y1150F and Y1151 mutations (He et al., 1998; Kasus-Jacobi et al., 1998) . This suggests that all three PIR recognize the same site on the insulin receptor. However, it is still unclear if the PIR binds directly a phosphorylated tyrosyl residue, or if the binding depends on a new epitope unmasked after spatial rearrangement of the kinase loop occurring after activation of the insulin receptors (Hubbard, 1997) .
The relative importance of the two domains, PIR and SH2, in the association with the insulin receptor, varies considering the member of the Grb7 family. The present study reports that the Grb7 interaction with the insulin receptor depends on both domains, although the SH2 domain seems to play the predominant role. In contrast, the PIR and the SH2 domains are equally implicated in the Grb10/IR interaction (He et al., 1998) , whereas the PIR is the main binding domain in the Grb14/IR interaction (Kasus-Jacobi et al., 1998; this study). The relative importance of the PIR and SH2 domains in the interaction with the insulin receptor is likely to be a determinant in the speci®city of this association.
Little information is available concerning the physiological role of Grb7, or Grb10 and Grb14. Although their function is not yet fully elucidated, it has been suggested that Grb10 and Grb14 are negative regulators of the insulin signal transduction (KasusJacobi et al., 1998; Liu and Roth, 1995) . Thus, it should be interesting to test if Grb7 also acts negatively on the insulin transduction pathways. The role of Grb10 has been extensively studied, but it is still unclear if it acts as a positive or a negative mediator of growth factor induced mitogenesis (Morrione et al., 1997; O'Neill et al., 1996; Wang et al., 1999) . One possible explanation could be that the dierent Grb10 isoforms display dierent functions. This is in good correlation with the recent study reporting a role for a new splice variant of Grb7 in cell invasion and metastatic progression of tumors (Tanaka et al., 1998) . Interestingly, in mouse and rat the expression of Grb7 mRNA is restricted to few tissues: there is a high level of expression in liver and kidney, and a low one in ovary, testes and lung (Margolis et al., 1992; and unpublished data) . It has recently been reported that Grb7 is a physiological factor important during the development of kidney (Leavey et al., 1998) . One can then anticipate that Grb7 plays also a physiological role in the liver, which is an important target of insulin actions. Nevertheless, identi®cation of the downstream signaling partners of Grb7 will be a necessary step to get inside the biological role of this protein.
In conclusion, we have shown that Grb7 binds the activated insulin receptor in vitro and in vivo. This association implicates two domains of Grb7, PIR and SH2, the phosphorylated tyrosine kinase loop and probably another undetermined region of the receptor. The observation that the importance of the SH2 and PIR domains varies for the interaction with the insulin receptor is interesting considering the signaling speci®city of the dierent members of the Grb7 family of proteins, and their potential role in the development of cancer. Indeed, after receptor binding, the Grbs proteins can recruit signaling factors through the remaining available protein-protein interacting domains, and then initiate various signaling pathways.
Materials and methods

Material
Synthetic de®ned dropout yeast media lacking the appropriate amino acids were obtained from BIO 101 (La Jolla, CA, USA). Oligonucleotides were purchased from Life Technologies. Monoclonal antiphosphotyrosine antibody (pY20), and polyclonal antibodies against the insulin receptor b-subunit and Grb7 were from Transduction Laboratories. Anti-LexA and anti-Gal4 activation domain antibodies were from Clontech (Palo Alto, CA, USA). All chemicals were from Sigma France, and enzymes from New England Biolabs (Beverly, MA, USA).
Plasmid constructions
The insulin receptors constructs in the two-hybrid vectors were previously described (Kasus-Jacobi et al., 1998) . The intracellular domain of the EGF receptor and of the FGF receptor were ampli®ed by PCR and cloned in the two-hybrid pACTII vector. The Grb7 deletion constructs were generated by PCR using appropriate primers and inserted at the BamHI site of pACTII and of pGEX3X (Amersham Pharmacia Biotech). The Grb7 constructs were as follows: WT Grb7, amino acids 1 ± 535; Grb7 DSH2, amino acids 1 ± 438; Grb7 DPIR ± SH2, amino acids 1 ± 347; Grb7 PIR ± SH2, amino Figure 6 Insulin receptor binding on PIR and SH2 domains of Grb7 and Grb14. The indicated GST ± Grb7 fusions (5 mg) were incubated with CHO ± IR lysates as described in Figure 2a . Bound proteins were immunodetected using anti-phosphotyrosine antibodies acids 345 ± 535; Grb7 SH2, amino acids 428 ± 535; Grb7 PIR, amino acids 345 ± 438. The Grb7 mutation of the arginine 461 into lysine (Grb7 R46K) was performed by site-directed mutagenesis using the Quick Change site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The pGAD ± Grb7 vector isolated during the two-hybrid screen (Kasus-Jacobi et al., 1998) contained a SpeI ± XbaI insert encoding the full length Grb7 protein. This insert was ligated in the XbaI site of the pECE vector (Ellis et al., 1986) , generating the pEGrb7 plasmid. All constructions were veri®ed by DNA sequence analysis. The GST ± Grb14 constructs, GST ± PIR and GST ± SH2 were described previously (Kasus-Jacobi et al., 1998).
COS cells transfections
COS cells were grown in DMEM (supplemented with 1 mM glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin and 10% FCS). Coexpression of the insulin receptor and Grb7 was performed by transient transfection of pET (containing the human IR cDNA (Ellis et al., 1986) ) and pE-Grb7 vectors using the DEAE-Dextran chloroquine technique. Brie¯y, cells were incubated in serum free DMEM containing 1 mg/ml DEAE-Dextran and 15 mg of DNA for 1.5 h, then in chloroquine 10 74 M for 3.5 h, and submitted to 5% DMSO for 5 min.
Immunoprecipitation and Western blotting
COS cells were used 24 h after transfection. SK-BR-3 cells were grown in DMEM (supplemented with 1 mM glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin and 10% FCS). The cells were serum depleted for 24 h, stimulated or not with insulin (10 77 M, 10 min) and solubilized at 48C in lysis buer as previously described (Kasus-Jacobi et al., 1998) . After a 15 min centrifugation at 15 000 g the supernatant was incubated overnight at 48C with anti-Grb7 antibodies in the presence of protein-A sepharose. The resulting immunoprecipitates were subjected to SDS ± PAGE electrophoresis and immunodetected with the indicated antibodies. The immunoreactive bands were revealed using the ECL detection kit (Amersham Pharmacia Biotech). For in vivo studies in rat, animals were starved for 24 h, anaesthetized, and injected with saline or insulin via the saphenous vein. After 10 min, the liver proteins were extracted and analysed, as previously described (Kasus-Jacobi et al., 1998) .
Two-hybrid experiments
Yeast strains were cotransformed with the two plasmids encoding the pLexA and pGAD hybrid proteins by the lithium acetate method of Gietz (Gietz et al., 1992) . Quantitative analyses of û-galactosidase activity were performed using a solution assay as described previously (KasusJacobi et al., 1997) . The Ras-Raf interaction was measured in each experiment as a positive control, and was 40+4 units of Miller. Yeast protein extracts were performed with glass beads according to the manufacturer's protocol (Clontech, Palo Alto, CA, USA). Extracts were subjected to SDS ± PAGE analysis, and hybrid proteins were detected using antiLexA and anti-GAL4 AD antibodies.
In vitro interaction studies GST fusion proteins were produced as described previously (Kasus-Jacobi et al., 1997). CHO-IR cells were serum starved for 24 h, stimulated or not with insulin (10 77 M) for 10 min at 378C. Cells were solubilized at 48C, in 20 mM Tris-HCl (pH 7.4) buer containing 150 mM NaCl, 10 mM EDTA, 1% Triton X-100, 0.1% BSA, and a standard cocktail of protease inhibitors (Complete, Boehringer Mannheim), in addition to 2 mM phenylmethylsulfonyl¯uoride, 20 mM NaF and 20 mM NaVO 3 . After a 15 min centrifugation at 15 000 g, the supernatant was incubated overnight at 48C with immobilized GST fusion proteins (5 mg of each). After extensive washing bound proteins were eluted by heating in SDS sample buer, and separated by SDS ± PAGE, transferred to nitrocellulose membranes, immunoblotted with the indicated antibody, and revealed as described above.
